Active pharmaceutical ingredients are delivered through pathogen cell walls using Phillips’ drug delivery technology.
When the active pharmaceutical ingredients are combined with tetracycline, the resulting product is a broad spectrum over-the-counter (OTC) antibiotic, which can be administered topically.
The tests for the new antibiotic drug demonstrated that it is effective against topical gram-negative and gram-positive bacteria.
PharmaCline is seeking Series C funding partners to support upcoming US and international OTC product launches.